Ocrelizumab (US)

DRUG3 trials

Sponsors

Amgen, Northwestern University, Washington University School of Medicine

Conditions

Multiple SclerosisMultiple Sclerosis (MS) - Relapsing-remittingRelapsing-remitting Multiple Sclerosis (RRMS)

Phase 3

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Active, not recruitingNCT06700343

AmgenRelapsing-remitting Multiple Sclerosis (RRMS)

Start: 2025-01-13End: 2027-10-04Updated: 2026-07-27

Unknown Phase

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

RecruitingNCT07207148

Northwestern UniversityMultiple Sclerosis

Start: 2025-11-15End: 2028-08-31Target: 100Updated: 2026-03-17

Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.

RecruitingNCT07758270

Washington University School of MedicineMultiple Sclerosis (MS) - Relapsing-remitting

Start: 2026-08-15End: 2030-08-29Target: 15Updated: 2026-08-11